BioSpace News Archive

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, provided a preliminary 2022 year-end corporate update.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection.

C4 Therapeutics, Inc. announced 2023 strategic priorities to advance its portfolio of targeted protein degradation medicines.

HilleVax, Inc. announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer, and the promotion of Shane Maltbie to Chief Financial Officer.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the initiation of the VEGA-2 Phase 3 pivotal trial with the first patient enrolled in late December.

Bausch + Lomb Introduces Enhanced PreserVision ® AREDS 2 Formula Mini Soft Gels with OCUSorb ™.

ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).

Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.

Xencor, Inc. today announced 2023 corporate priorities and provided multiple clinical development updates.

Spruce Biosciences, Inc. today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).